CIK 0001703647
- Non-accelerated filer
- Smaller reporting company
Korro Bio, Inc.
Sign in to watch- Ticker
- KRRO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472324450
- Phone
- +1 617-468-1999
- Business address
- 60 FIRST STREET, 2ND FLOOR, SUITE 250, CAMBRIDGE, MA, 02141
- Former names
- Frequency Therapeutics, Inc.
- Open-market buys, last 90 days
- $884,752
- in 1 filing
- Open-market sales, last 90 days
- $1,763,410
- in 5 filings, $1.8M under 10b5-1 plans
Net −$878,658. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 5 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-01 | Lucchino David L. President and CEO | Sale | −8,900 | $43.71 | $389K | 310,788 |
| 2021-02-01 | Lucchino David L. President and CEO | Sale | −2,702 | $44.58 | $120K | 308,086 |
| 2021-02-01 | Lucchino David L. President and CEO | Exercise or conversion · Stock Option | −33,102 | 204,549 | ||
| 2021-01-29 | McCubbin Quentin Chief Manufacturing Officer | Grant or award · Stock Option | +90,000 | 90,000 | ||
| 2021-01-27 | Lucchino David L. President and CEO | Exercise or conversion | +9,196 | $0.61 | $6K | 317,282 |
| 2021-01-27 | Lucchino David L. President and CEO | Sale | −9,196 | $42.50 | $391K | 308,086 |
| 2021-01-27 | Lucchino David L. President and CEO | Exercise or conversion · Stock Option | −9,196 | 237,651 | ||
| 2021-01-27 | Loose Christopher R. Chief Scientific Officer | Sale | −8,000 | $42.50 | $340K | 31,782 |
| 2021-01-15 | Loose Christopher R. Chief Scientific Officer | Grant or award · Stock Option | +70,000 | 70,000 | ||
| 2021-01-15 | Lucchino David L. President and CEO | Grant or award · Stock Option | +200,000 | 200,000 | ||
| 2021-01-15 | Arnold Wendy S Chief People Officer | Grant or award · Stock Option | +75,000 | 75,000 | ||
| 2021-01-15 | LeBel Carl Chief Development Officer | Grant or award · Stock Option | +75,000 | 75,000 | ||
| 2021-01-15 | Hilt Dana Charles Chief Medical Officer | Grant or award · Stock Option | +70,000 | 70,000 | ||
| 2021-01-15 | PFREUNDSCHUH PETER P. Chief Financial Officer | Grant or award · Stock Option | +10,000 | 10,000 | ||
| 2021-01-06 | Lucchino David L. President and CEO | Exercise or conversion | +27,586 | $0.61 | $17K | 335,672 |
| 2021-01-06 | Lucchino David L. President and CEO | Sale | −900 | $36.13 | $33K | 334,772 |
| 2021-01-06 | Lucchino David L. President and CEO | Sale | −10,707 | $37.45 | $401K | 324,065 |
| 2021-01-06 | Lucchino David L. President and CEO | Sale | −4,164 | $38.26 | $159K | 319,901 |
| 2021-01-06 | Lucchino David L. President and CEO | Sale | −2,319 | $39.37 | $91K | 317,582 |
| 2021-01-06 | Lucchino David L. President and CEO | Sale | −9,496 | $40.00 | $380K | 308,086 |
Page 25 of 34 · 670 trades